1Department of Biochemistry, Tanta University, Egypt
2Department of Clinical Pharmacy, Delta University, Egypt
Background: The efficacy of a non-prescription drug to support weight loss programs has yet to be compared. This clinical trial investigates the comparability of the lipase inhibitor orlistat and the dopaminergic agonistbromocriptine.
Methods: Seventy five obese females were randomized into three groups according to treatment received; obese control group (OC; n = 25), orlistat group (OR, n = 25, 120 mg capsules, three times a day) and bromocriptine group (OB, n= 25, 20 mg tablet, once a day). This prospective observational study was conductedwith normocaloric diet for eight weeks. Serum concentration of leptin and lipid profile were measured, along with body Mass Index (BMI) at baseline and after the study.
Results: Bromocriptine treatment(OB) caused an increase in serum leptin concentration compared to OC and OR groups (ANOVA, p < 0.01). Beneficial changes in anthropometric and BMI values were observed following orlistat and bromocriptine administration with the greatest advantage seen in the OB group.
Conclusions: Beneficial effects were observed on weight loss, and body composition in all examined groups, with the greatest advantage on serum leptin being associated with the bromocriptine treatment. We find these strategies more promising for the treatment of obesity and its related complications in obese women.
Keywords: Obesity, Bromocriptine, Orlistat, Weight loss, Leptin
Biography:
Dr. Ghada Mohammad has completed her Ph.D. in Pharmacy (Biochemistry), Tanta University, Egypt in the year September 2015, Master Degree in Biochemistry, Tanta University, Faculty of Pharmacy, Egypt, B.Sc. Degree in Pharm. Sciences (Excellent Honor) Tanta University, Faculty of Pharmacy, Egypt. Currently she is a Lecturer in Biochemistry Department at Tanta University, Faculty of Pharmacy, Egypt. She has a Membership in Professional Associations (1)Egyptian Syndicate of Pharmacists, (2) HYPERLINK “https://www.facebook.com/CECR.TantaUN/?ref=page_internal”Egyptian Association for Cancer Research (EACR), (3)Egyptian Society of Clinical Chemistry.
Delhi Pharmaceutical Science and Research University, India
Efficient dual targeted chemotherapy is an attractive approach for killing the tumor cells and tumor endothelial cells, while sparing the normal tissue. Herein, we investigated whether encapsulation of paclitaxel (PTX) within polymer–lipid hybrid nanoparticles conjugated with kNGR (PLNs-kNGR) achieved this goal in a subcutaneous tumor induced Balb/c mice bearing HT-1080 tumor model with nanocarrier-modified biodistribution and toxicity. The dual targeted PLNs-kNGR was prepared by modified nano-precipitation technique combined with self-assembly and evaluated for different parameters. Compared with other tested NPs, PLNs-kNGR-NPs revealed more cytotoxicity by inducing more apoptosis, higher intracellular uptake and % tumor volume inhibition rate that was 59.7%. These findings substantiate the importance of rational design of nanoparticles for dual targeting synergistic therapy. As a consequence, the PLNs-kNGR-NPs play a key role in enhancing tumor therapeutic efficiency for treatment of CD13 receptor specific solid tumor.
Keywords: kNGR peptide, CD13 receptor, targeted therapy, polymer lipid hybrid nanoparticles, intracellular delivery.
Biography:
Dr. Madhu Gupta has research experience pertaining to drug delivery to nanoformulations for magical molecule delivery, bioligands for targeting of bioactives and drug moiety, biopolymers, cancer nanomedicine as well as topical delivery that is carried out at Department of Pharmaceutical Sciences, Dr. H.S. Gour Central University, Sagar. Dr. Gupta has done her B. Pharm (Gold Medalist), M. Pharm., Ph.D. in Pharmaceutics with experience of more than 10 years in academics, administrative functions and research in areas of Pharmaceutical nanotechnology and targeted drug delivery related to cancer, fungal infection, and psoriasis.
Presently she is working as an officer on Special duty to Vice-Chancellor, in Delhi Pharmaceutical Sciences and Research University. Along with teaching and research, she is member secretary of World Class skill Centre courses, PRO, Web site In-charge, IQAC incharge as well as hostel warden. Dr. Gupta is the course co-ordinator for Cosmeceutics in the university. She has worked as Associate Professor and Departmental head (2013-2016), Research and Academic Coordinator Coordinator (2013-2016), Training and placement officer (2031-2016), Library incharge (2013-2016), Coordinator, Industrial training, Industrial visits and expert lectures (2013-2016), Coordinator for organizing conferences, seminars in Shri rawat Pura Sarkar Institute of Pharmacy, Datia M.P.
She is pioneer scientist in the field of nanotechnology and drug delivery field. She has judiously exploited bioligands for targeting of bioactives and drug moiety. She has over 35 research publications to her credit published in journals of high scientific impact and contributed 14 chapters in various renowned books and to several international and national books. Dr. Gupta has H-index of 11, i10-index of 11 and more than 500 citations. She has the awardees of various national and International conference in the form of best oral and poster presentation award. She has supervised 13 M.Pharm students. Dr. Gupta has availed several prestigious fellowships and awards SRF AICTE (NDF), JRF (AICTE), Travel grant awards (DST, ICMR, INSA, and DBT, MPCST), Prof. G.P. nait Award (2004), Prof. C.S. Chauhan Award (2004). She has her research work at Bio Asia Innovation Award – 2012. She is successfully complete one project that is funded by MPCST Bhopal.
She is the nominee of CPCSEA and also active member of various Pharmaceutical body such as APTI and other. She is reviewer of various journals of repute. She has attended various conferences/seminars/workshops/FDPs as organizer/co-ordinator/resource person/participant. Dr. Gupta and her team has been selected for funding of 1 start-up.
1Division for Pharmacy Practice and Policy, University of Nottingham, UK
2Division of Pharmacy and Optometry, The University of Manchester, UK
3Nottingham University Hospitals NHS Trust, Nottingham, UK
Background: The study aimed to describe the characteristics and prescribing patterns of non-cancer pain patients using strong opioids long-term, and explore factors associated with the utilisation.
Method: This retrospective, longitudinal study used the Clinical Practice Research Datalink (CPRD). Prescriptions of four strong opioids (morphine, buprenorphine, fentanyl and oxycodone) issued to adult patients (aged ≥18 years) between 2000-2010, who were without a cancer diagnosis 12 months within the first prescription use were included. Total number of prescriptions, total dayʼs supply and total oral morphine equivalent dose were calculated for each patient per year. Long-term strong opioid supply was defined as ≥ 90 days in a year and high dose use as an average oral morphine equivalent dose >120mg/day in a year. Baseline (demographics, pain condition, comorbidity, socioeconomic status, geographic region) and time-dependent (number of GP visits, co-prescribing psychotropic medications) associated with long-term use were assessed using the generalized estimating equations.
Results: Of the 113, 428 non-cancer strong opioid users included in the study, 26, 703 (23.54%) were long-term users with a mean follow up of 4.48±3.02 years. Majority (64.99%) of long-term users were females, and the mean age was 65.31±17.07 years. Their mean annual opioid treatment duration was 249.81±90.39 days and the mean annual OMED was 95.88±109.02 mg/day. Twenty-six (n=6, 945) percent of long-term users received high-doses. Their mean annual OMED was 221.19±148.07 mg/day and mean duration of supply was 277.05±84.55 days/year. After adjusting for age, gender and geographic region; high Townsend deprivation score (aOR: 1.13; 95% CI: 1.06, 1.20), greater numbers of GP consultations per year (aOR: 3.66; 95% CI: 3.50, 3.83), co-prescriptions of psychotropic medications including antidepressants (aOR: 1.80; 95% CI: 1.75, 1.86) and benzodiazepines (aOR: 1.07; 95% CI: 1.03, 1.11) were associated with long-term strong opioid use per year, significant at p<0.001.
Conclusions: Long-term strong opioid use was linked to a number of socio-demographic factors and a subgroup of long-term users received high mean daily dose that was 1.5 times greater than recommendations in British guidelines. Further research is needed to establish risks and benefits of strong opioid use in primary care.
Biography:
Dr. M Adan is a qualified Pharmacist and a Research fellow. She graduated from the University College London gaining a Master of Pharmacy degree and completed her Pre-registration training in 2008 in a split placement between Quys and Stʼthomas and Queen Maryʼs hospital in London. Muna subsequently worked in various community pharmacies as a Pharmacist before pursuing a doctoral degree from the University of Nottingham in late 2012. Her thesis focused on analyzing long-term prescribing patterns and outcome measures of strong opioid use in patients with non-cancer pain (such as back pain and fibromyalgia). She gained her PhD in 2017 from the University of Nottingham.
1Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, India
2Department of Pharmacology, Manipal College of Pharmaceutical Sciences, India
Aseries of novel Schiffʼs bases were synthesized by single step process of condensing substituted 2-amino benzothiazole with different benzaldehydes. Atotalof 18 compounds were synthesized and characterized by FTIR, 1HNMR, and Mass spectroscopy. The synthesized compounds were tested in-vitro for both antioxidant and antiproliferative activity. Unfortunately, none of the compound showed comparable antioxidant activity with that of ascorbic acid (0.063µg/ml) even though the majority of the derivatives displayed moderate to significant antiproliferative activity on HeLacellline. Interestingly, the compound SP16 showed excellent activity with an IC50 value of 2.517µg/ml incomparison to the reference compound Cisplatin (17.2µg/ml). In-silico docking studies were performed to identify the interactions and binding mode of the synthesized Schiff bases on the crystal structure of the complex of caspase-3 with a nicotinic acid aldehyde inhibitor with PDB ID 1RE1, 1RHM and 3DEH.
Biography:
Dr. Suvarna G Kini is an Professor and researcher in the Department of Pharm. Chemistry, Manipal College of Pharm. Sciences, MAHE, Manipal, INDIA.B.Pharm and M.Pharm for Government College of Pharmacy, Bengaluru, Karnataka, INDIA. PhD from MCOPS, MAHE, Manipal, Karnataka, INDIA. Area of Research includes Design, synthesis and docking studies of novel heterocyclic compounds and their biological screening and Development of method of analysis for new drugs. Current research interest is in developing small organic molecules for treating colorectal and cervical cancer. Authored 38 national and international publications. Received grant from Dept. of Biotechnology, INDIA under BIOCARE scheme for research on cervical cancer [BT/PR18194/BIC/101/631/2016].
1Horizon Blue Cross Blue Shield of New Jersey, USA
2Rutgers State University of New Jersey, USA
3Magellan Rx Management, USA
In 2015, approximately half of all specialty drug spend was billed under the medical benefit. 1In that same year, the FDA approved a record-setting 45 novel medications, including 6 biologic agents, besting its ten year average approval rate of 28 novel drugs per year. 2In 2016, the FDA approved 13 new drugs that fell under the medical benefit. These approvals included four drugs in the oncology space, three drugs for bleeding disorders, and two for rare pediatric neuromuscular disorders. With the flood of specialty biologics to the market, drugs billed to the medical benefit continue to be cost drivers for the overall drug trend. Since 2011, drug spend on the medical benefit has increased by 55%. 3The overall per member per month spend for commercial members for medical benefit drugs was $23.68 in 2015, with oncology agents making up approximately half of that spend. 3Other specialty categories such at biologic drugs for autoimmune disorders, immune globulins, antihemophilic factor products, multiple sclerosis, and rare and orphan disease agents also make up a large chunk of the drug spend on the medical benefit, representing about 76% of the total medical drug spend in 2015. 3Because of these factors, effective management of specialty drugs on the medical benefit is critical to controlling drug spend and trend.
A variety of strategies can be used to manage specialty spend on the medical benefit including appropriate utilization management through prior authorization and claim editing, site of care management, and reimbursement strategies that drive utilization towards generics and low cost alternatives. Identification of high cost members and outlier management can be another crucial component to effectively management cost. Overall, effective management strategies can yield a 10%-20% savings on medical benefit drug spend.
Biography:
Dr. Jan is the clinical professor at Ernest Mario School of pharmacy at Rutgers University of NJ and leads the Horizon Blue Cross Blue Shield of New Jersey pharmacy clinical management program as a Clinical Director with over 19 years of experience in health care management and research and academics. She has implemented many clinical programs such as Opioid management, Rheumatoid arthritis, Star measures, MTM, adherence and childhood obesity initiatives in the state of New Jersey in addition to serving as a consultant to many industry foundations and committees. Dr. Jan has a Masters in Pharmacology from St Johnʼs University and a doctorate in Pharmacy from Rutgers State University of New Jersey.
1The Cyprus Institute of Neurology and Genetics, Cyprus
2Palupa Medical Ltd, Cyprus
3School of Medicine, European University Cyprus, Cyprus
Introduction: MS treatments are products of reductionism, partially effective with no (re)myelinating/neuroprotective abilities associated with significant side-effects. We aimed to assess whether our novel interventions, formulated based on systems medicine (SM), comprising specific polyunsaturated fatty acids (PUFA) and vitamins reduce disease activity in patients with relapsing remitting (RR) MS who were either treated with disease modifying treatment (DMT) or untreated.
Methods: We contacted a 30-month randomized, double-blind, placebo-controlled, proof-of-concept clinical study at the CING. Of a total of 80 patients, 20 were randomly assigned to receive intervention A (docosahexaenoic acid (DHA)/eicosapentaenoic acid (EPA) (3:1w/w) omega-3, linoleic acid (LA)/gamma(g)-linolenic acid (GLA) (2:1w/w) omega-6 fatty acids, omega-3/omega-6 (1:1w/w), other specific PUFA, monounsaturated fatty acids (MUFA), minor quantity of specific saturated fatty acids (SFA), vitamin A and vitamin E), 20 to receive γ-tocopherol, intervention C, 20 to receive the combination of A and C, intervention B (PLP10) and
20 to receive placebo, as an oral solution, once daily. The primary end point was the annualized relapse rate (ARR) and the key secondary end point was the time to disability progression. ISRCTN87818535.
Results: PLP10 reduced the ARR by 70% (p=0.003), in relation to the baseline ARR and the placebo increased by 46% (p=0.354). For the primary end point, PLP10 reduced the ARR by 58% (p=0.016) and for the secondary end point, significantly reduced the risk of sustained progression of disability by 86% over the 2-year period (p=0.047) vs. placebo. More patients in the PLP10 group (72%) vs. placebo group (20%) were free from new or enlarging T2-weighted lesions on brain MRI scans over the 2-year study. No adverse events were reported. Interventions A and C showed no significant efficacy.
Discussion: PLP10 treatment significantly reduced the ARR, and the risk of sustained disability progression without any adverse or significant side effects. This is the first clinical study of SM approach medical nutrient formula that holds strong promise as an effective treatment for RRMS.
Biography:
Dr. Ioannis S Patrikios completed his PhD studies in Biochemistry in 1994, from the City University of New York, USA. Recently he was offered and now serves as a Fellow of the Academy of Forensic Medical Science, UK and member of the Advisory Board. His 2002 research findings on the effect of frying oils as human hemagglutinins got an international interest. He has been appointed as a reviewer of international scientific journals in the field of Medicine, Med-Biochemistry, Pharmaceuticals-Therapeutics and Neurology and as a reviewer for research grants. Professor Patrikios is the founder and solid organizer of the annual event “International Multithematic Medical Congress, Biomedical Scientific Cyprus (BSC)” an International annual scientifically prestigious congress. He is a member of several International associations and bodies including Sigma Xi. He is the chief scientific investigator of the team that lately invented and patented the nutraceutical formula Neuroaspis® PLP10 as a new therapeutic intervention for multiple sclerosis. At present, he serves as the Acting Chairman of the School of Medicine, European University Cyprus and affiliated as a research collaborator at the Cyprus Institute of Neurology and Genetics, Cyprus.
1Department of Drug Design and Pharmacology, University of Copenhagen, Denmark
2Department of Pharmacy, University of Copenhagen, Denmark
3Institute of Biophysics, National Research Council of Italy, Italy
4Institute of Physics, National Research Council of Italy, Italy
Protein amyloid-like aggregation is related to devastating pathologies as Alzheimerʼs and Parkinsonʼs diseases. During this process, the protein native state converts into a partially unfolded non-native state and then associates into smaller, soluble oligomers of different sizes. Subsequently, elongated fibrils are formed (i.e. fibrillation). In some protein system, also amyloids-like superstructures (spherulites) have also been found in vitro during the aggregation (1, 2) and in vivo (3, 4). Importantly, monomers, oligomers, fibrils, and spherulites coexist in an equilibrium that is influenced by the environment (5, 6). It is known that water, co-solutes, small molecules, concentrations, temperature, etc., play a crucial role in the native state of proteins, changing the structure and influencing inter-protein interactions. In this study, we aim to demonstrate how the chemical-physical composition of the solutions as well as the temperature, not only affect the protein initial states but also the dynamic of the fibrillation, the equilibrium between the species formed and the morphology of the mature fibrils (7). Also, our results emphasize that the final state of the fibrillation is not a stationary state but still a dynamic system that also after have been formed it can be highly influenced by incubation at different temperatures, pH and times.
Biography:
Dr. Carlotta Marasini is a physicist with a specialization in biophysics. Her specialization focuses on the study of different proteins involved in several diseases combining biophysical and biochemical techniques. During her masters, she spent six months at the ILL in Grenoble studying the aggregation of insulin by neutron scattering. She received her Ph.D. in bioengineering from the University of Genoa in 2013, performing a structural study of a protein responsible for Cystic Fibrosis disease. She was worked as postdoc at the University of Copenhagen, She is studying analysis the structure and kinetics of different proteins involved in neurodegenerative diseases.
Nova Southeastern University, USA
The clinical evidence for interactions between conventional drugs and herbal medicines is steadily increasing globally. This can be attributed to many factors including increasing trends towards consumption of herbal supplements for various health benefits, loose regulation of the herbal drug industry, and the need for proper training of healthcare professionals on the potential hazards of herbal supplements. Herbs contain potent chemical constituents that can affect both the pharmacodynamic and pharmacokinetic profiles of conventional drugs when simultaneouslyadministered. The mechanistic basis for these interactions include antagonism or potentiation of therapeutic effects, and altered absorption, metabolism or elimination of drugs. Many herbs have been implicated in these regards. Garlic (Allium sativum) has been shown to increase risk for bleeding in patients on warfarin; Licorice (Glycyrrhizaglabra) antagonizes the effects of anti-hypertensives; Green tea (Camellia sinensis) impairs the absorption of nadolol; and St Johnʼs Wort (Hypericumperforatum) induces the metabolism of cyclosporine and numerous other drugs that are dependent of the cytochrome P450 enzymes for biotransformation. Based on these lines of evidence, there is a still a greater need for education of health care providers and patients about the risks of herbal medicines and for integration of evidenced-based herbal medicine knowledge into curriculums of medical schools globally. Additionally, further clinical research and pharmacovigilance is needed to gather more evidence on the incidence of drug-herb interactions and patient outcomes in this unique setting. This data would have significant implications towards guiding the development of stricter regulations for the herbal drug industry.
Biography:
Dr. Arkene Levy is an Associate professor of Pharmacology and Pharmacognosy at the Nova Southeastern University in Florida USA. Dr. Levy completed her PhD in Pharmacology at the University of the West Indies in Jamaica, and postdoctoral studies as a Fulbright Scholar at Mooreʼs Cancer Centre, UCSD California. Dr. Levy has extensive research experience on the effects of natural products in cancer and inflammatory disease models. Dr. Levy is an editorial consultant for the Current Topics in Nutraceutical Research journal and a member of both the American Society for Pharmacology and Experimental Therapeutics and the American Association for Cancer Research.
JNTU University, India
Cancer is a dreadful disease and any practical solution in combating this disease is of paramount importance to public health. Cancer patients have burdened by drug induced toxic side effects, and no turned to seek help from the complementary and alternative medicine hoping for a better cure. Research on Platinum based drugs and Non Platinum based drugs is a Multi-Million Dollar Industry in USA and there is every need to produce safe drugs for the cure of this monstrous disease. Flavonoids have a long history of use in traditional medicines in many cultures. The phytochemical, curcumin is one of the major dietary flavonoid, belonging to a group of flavonol, Curcumin is a natural polyphenol. It is highly potential molecule capable of preventing and treating various cancers. Various dietary chemo preventive agents, turmeric powder or its extract are broadly used as therapeutic preparations in Indian System of medicine. We provide a summarized synthesis and structural determination of Curcumin Oxime, Curcumin Thiosemicarbazone derivative of Gold (III) complex. The use of these analogs for prevention of cancer tumor progression and treatments of human malignancies. A pharmacologic agent for treating and/or preventing cancer, among other diseases and conditions, and particularly breast, prostate, and pancreatic cancer, in humans and animals. The novel pharmacologic agent is an isoflavonoid or isoflavonoid mimetic covalently attached to a cytotoxic pharmacophore that, preferably has the ability to conjugate with a metal salt to form a more potent metal complex, particularly a Au (III) complex and other complexes of Platinum, Palladium, Ruthenium, Copper etc.
My talk would mainly encompass different Transition Metal Complexes/Organometallic Compounds that are presently used as drugs, especially Anticancer and Anti-HIV drugs, apart from Anti-inflammatory, Antimicrobial, Antibacterial and diseases like Arthritis and Parkinsonʼs Disease etc. The talk would mainly focus on the use of Medicinal Chemistry and itʼs application to Drug Design and Development in Pharmaceutical Industry, especially Transition Metal Complexes and Organometallic Compounds viz. Gold, Platinum, Palladium and Ruthenium apart from Copper, Cobalt, Iron, Nickel, Zinc, Cadmium etc.
The main emphasis of my talk would be on Different class of Ligands, their Schiffʼs Bases and Transition Metal Complexes especially Au, Pt, Pd and Ru, with the main aim of designing, developing very novel small molecules, as possible and extremely potential candidates as Anti-cancer and Anti-HIV drugs. The talk would provide an overview of current programs being undertaken in our laboratories, especially focused on the development of potent ligands capable of recognizing Binding sites and diverse strategies employed by my group for elucidation of Anti-Cancer and Anti-HIV drug Leads to Circumvent the problem caused by Cis-Platin.
We have synthesized and characterized several phytochemicals from Traditional Medicinal Plants and isolated some phytochemicals and made the corresponding Oximes, Thiosemicarbazones and Substituted thiosemicarbazones as ligands and synthesized, characterized, structurally elucidated their Transition Metal Complexes especially with Gold, Platinum, Palladium, Ruthenium, Copper etc. and Studied their Anticancer Activity, Nuclease activity etc. and tested their potential as Anticancer Drugs.
The main aim of our extensive/preclinical Pharmaceutical development program is to investigate the use of these extremely novel small molecules-metal complexes/compounds of phytochemicals, flavanoids etc., which have very interesting structural features and properties and hence are excellent candidates as Anti-Cancer and Anti-HIV drugs. The main aim of our research is Design, Development and Synthesis of Transition Metal Complexes/ Organometallic Compounds that would certainly help to bring this force of nature from BENCH to BEDSIDE and enhance Cancer Killing with less toxic effects and would certainly lead to initiation of clinical trials.
Biography:
Prakash Kinthada is a Professor in Chemistry at Sri Vidyanikethan Engineering college, JNTU University in Ananthapur, A. Rangam Peta, Tirupathi, India.
Department of Pharmacy, School of Medicine, University of Naples Federico II, Italy
Interleukin-17A (IL-17A) is the most studied member of the IL-17 cytokine family. It is mainly produced by T-helper (Th)-17 lymphocytes, and also by cytotoxic CD8+ T cells (Tc17), γδT cells (γδ-17), natural killer T (NKT) cells and neutrophils (1). This cytokine elicits protection against extracellular bacterial and fungal infections and, when produced in excess, it contributes to chronic inflammation (2).
Since its discovery, much attention has been given to mediators and factors responsible for the development of IL-17-producing cells while very few studies have investigated the inflammatory properties of this cytokine and signaling pathways involved in its physio-pathological functions.
A growing number of evidences gathered over the last few years indicate that IL-17A might play a key role in sustaining chronic inflammation in patients suffering from autoimmune diseases (such as rheumatoid arthritis, psoriasis, multiple sclerosis and some bowel inflammatory diseases) and probably in the hemostatic disorders observed in these patients (3, 4).
Here, I summarize the most recent findings on the biological effects of these new inflammatory cytokine and discuss how these discoveries might influence our current view on therapeutic approaches to treat ongoing inflammation and inflammatory-related diseases.
Biography:
Dr. Francesco Maione Holds a PhD degree in Pharmaceutical Science (Cycle XXI), at the Faculty of Pharmacy, University of Naples Federico II. In the year 2009 he is the Winner of the specialization competition in hospital pharmacy at the University of Naples Federico II. His Research activity is in the field of Pharmacology of the cardiac, gastrointestinal and inflammation systems. The main research lines include the study of 1) role of the protein Annessin-1 (ANX-1) in inflammation and cardiovascular system 2) role of interleukin-17 (IL-17) in inflammation and platelet function 3) pharmacological characterization of active ingredients of natural origin. He has published n.36 works in estensi in international journals (peer-reviewed Journals).
1Saurashtra University, India
2L.M.College of Pharmacy, India
A simple, sensitive, and selective validated HPTLC method was developed for the simultaneous quantification of the isolated major active secondary metabolites in the bark of the plant Adenanthera pavonina viz. stigmasterol and lupeol. The Phytochemical screening of the bark of Adenanthera pavonina revealed the presence of steroids, terpenoids, phenolic compounds, saponins, and flavonoids. Stigmasterol and Lupeol were isolated from the bark of Adenanthera pavonina and were characterized by physicochemical and spectrophotometric methods. Simple and validated HPTLC method was developed for the simultaneous estimation of Stigmasterol and Lupeol in bark of Adenanthera pavonina. The separation was performed on TLC aluminium plates pre-coated with silica G60 F254 followed by detection of Stigmasterol and Lupeol by derivatizing the plate with vanillin- phosphoric acid reagent. Camag TLC scanner 3 equipped with CATS4 software was used for densitometric scanning at 550 nm. The proposed method was validated in terms of linearity, precision, accuracy and sensitivity as per the International Conference on Harmonization guidelines. The mobile phase optimized was Toluene: methanol (92: 8 v/v) with saturation time of 15 min which give the good resolution for Stigmasterol and Lupeol at Rf 0.43 ± 0.02 and 0.55 ± 0.02 respectively. The linearity was found to be within range 100-500 ng/spot with average % recovery of 95.16% for Stigmasterol and 400-2000 ng/spot with average % recovery of 95.3% Lupeol. The amount of Stigmasterol and Lupeol in bark of the plant was found to be 0.0743 and 0.146 %w/w.
Biography:
Ms. Bhagyashri Fachara has completed her M. Pharm (Quality Assurance) at the age of 23 years from Gujarat Technological University. She is the recipient of M. L. Schroff Medal-2012 from Indian Pharmaceutical Association for securing highest grade in B. Pharm (All over India). She is the recipient of Gold medal for M. Pharm as well as B.Pharm. Currently she is pursuing Ph. D studies as UGC-BSR research fellow from Department of Pharmaceutical Sciences, Saurashtra University, Gujarat, India.
King Abdulaziz University, Saudi Arabia
The number of hospitals in the United States who reported the presence of emergency department (ED) clinical pharmacy services increased from 3.4% in 2006 to 16.4% in 2014 according to survey data. In 2011, the American Society of Health-System Pharmacists (ASHP) published Guidelines on Emergency Medicine Pharmacist Services. In Saudi Arabia, the provision of clinical pharmacy services in the ED is relatively new. Currently, ED pharmacy services in Saudi Arabia are limited to outpatient dispensing and medication history collection. A small number of Saudi EDs have recently started to assign pharmacists to provide limited direct patient care services such as (Patient endorsement in the ED, order verification, and code blue participation). Optimizing the clinical pharmacy services in the ED shows reduction of medication errors, improvement of therapeutic plans and facilitate cost saving.
Biography:
Dr. Hussain Bakhsh, Pharm.D., BCPS, is assistant professor at The Faculty of Pharmacy, King Abdulaziz University. Dr. Bakhsh earned his Doctor of Pharmacy degree from King Abdulaziz University after which time he was the first Saudi who completed Pharmacy Practice Residency and Emergency Medicine Specialty Residency training at The University of Arizona.
Dr. Bakhsh completed a Postdoctoral Fellowship at The University of Arizona. His area of research includes: emergency medicine and toxicology.
Dr. Bakhsh is a Board-Certified Pharmacotherapy Specialist. He is a member of the American Society of Health-System Pharmacist (ASHP) and the American College of Clinical Pharmacy (ACCP).
Department of Pharmaceutics, Anand Pharmacy College, India
The major oral solid medicines are sold in blister and strips packaging, which are packaged in a carton box. Children, who manage to open such boxes while unsupervised, are in great danger of being poisoned by swallowing the contents. A child resistant packaging (CRP) usually requires a special trick to open it. The aim was to design and validate performance of innovative child resistant packaging (CRP) system with unique features. Materials used were plastic grade, click lock system, and blister pack. The test was conducted on test panels of 100 healthy children between 42 to 51 months old were asked to open a pack. Each panel was divided into 3 groups, viz. 30 children of 42 to 44 months old, 40 children 45 to 48 months and 30 children 49 to 51 months. The panel of 100 healthy adults were divided into 3 groups, viz. 25 adults 18 to 40 years old, 25 adults 40 to 59 years old, and 50 adults 60 to 70 years old. Results showed only 6 % children succeeded to open CRP, while 94 % were failed to open CRP within 5 min. In case of adults, 96 % succeeded to open CRP without imposing any difficulties. There was a successful development of prototype of CRP, which can be used for the packaging of pharmaceutical products. Child resistant packaging deprived children to have access of medicated packaging system which resulted in devoid of any poisonous effect to the children.
Biography:
Dr. Lalji Baldaniya is presently working as Assistant Professor at Anand Pharmacy College, He has 10 years of teaching and research experience. His area of research is formulation development of novel drug delivery systems, dissolution testing, PKPD study and innovation in pharmaceutical packaging systems. He has published more than 20 research papers in journals of national & international repute. He has also presented several papers in national & international conferences. He is recipient of the prestigious award from IPA ACG – SciTech Innovation 2016 in Solid dosage form development, and Pedagogical Innovation Award 2017. He has filed two patents. He involved in various research project sponsored by GUJCOST, BIRAC-SRISTI. He is reviewer of national & international journal in his research area of interest.
Department of Pharmacology and Toxicology, Taif University, Saudi Arabia
Medication error is any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in control of the health care professional, patient or consumer. Studies done since the 1970ʼs have shown the high incidences of medical errors and deaths resulting from them. Only 3% of physicians believe that medical errors are a principal health concern and yet, there is more concern with car accidents. Medical error statistics in the United States are enormous and alarming. The American medical system is the number one killer in the U.S. In ten years; the deaths caused by conventional medicine are approximately 8 million.
The proposal concerns with the determination of errors during the process of treatment such as self-medication, prescribing errors, lack of knowledge, lack of attention, poor drug selection and poor monitoring. The community pharmacy errors such as, wrong quantity, wrong drug, wrong dosage form, wrong strength and wrong information (label). Most of patient errors come from the drug administration, patient personality, education and culture. Health care cost savings, Improves the image of the pharmacist and helps pharmacy to become a true clinical profession. Teaching patients about their medication and their disease also help to prevent medication errors.
Most of countries have a statistical data concerning the medication errors and comparing these data may lead to reduce and detect the parameters of medication errors. This study Investigates the parameters of self-medication in the population and their relationship with the medication errors. The sample size of our study was 600 (n=600); healthcare professions (200) and public (400). The study suggests that participants agree that factors such as, knowledge, information, self-medication and organization have an impact on medication errors with 78.2%, 61.8%, 67.2%, 83.6%, respectively. The rate of medication errors in one tertiary hospital was about 40%.
Biography:
Dr. Majed Isa has a Citizenship of both Jordan and Belgium Married and have four children. All his high education conducted in Belgium at Brussels and Louvain University. Ph D degree in Pharmaceutical sciences obtained with the highest consideration in 1989 from Brussels University. Director and manager of research projects for many Pharmaceutical industrials in Belgium and Jordan. Currently he ia Professor of Pharmacology and Toxicology in Jordan, Palestine, Saudi Arabia.
Research interest in Pharmacology of Antibiotics and Anticancer drugs. Metabolism of drugs. Addiction, Biotechnology and environmental pollution.
He Published more than 50 Articles, four of them original in different international Journal. Participated in more than 30 conference, symposium and training staff in the world.
Warmia and Mazury University in Olsztyn, Poland
Peptides derived from food proteins affect biological, functional, immunological and sensory properties of food products. Proteins apart from their function as the nutrients act as the precursors of nutraceuticals with variety of functions. BIOPEP database of protein and peptide sequences has been designed mainly for scientists working in the area of food and nutrition (http://www.uwm. edu.pl/biochemia). BIOPEP database consists of sequence databases: proteins, bioactive peptides, allergenic peptides with their epitopes and sensory peptides. The information concerning peptide or protein covers its sequence; data about activity or taste; references or in the case of allergenic protein database reference, sequence of experimental and theoretically predicted linear epitopes. Sequence analysis options include the construction of profiles of the potential biological activity, epitopes or sensory activity, calculation of the quantitative parameters A and B useful for evaluation and classification of proteins as precursors of bioactive or sensory peptides as well as immunogenic fragments. The options available include also the simulation and design of proteolysis as well as data mining. BIOPEP contains also the collection of links to other databases and programs. Proposed workflows for use of database of bioactive peptide sequences cover among others: use sequences of peptides as queries for database screening or identification of peptides from BIOPEP among products of protein hydrolysis. Selected examples of applications of the database, described by other authors will be presented. To date, apart from the data concerning different biological properties of peptides, BIOPEP may serve as a tool supporting the experimental and theoretical studies on food-derived biopeptides.
Biography:
Dr. M. Darewicz received PhD in agricultural sciences in 1992. In 1997 she was visiting scientist in Danish Technological Institut, in 1998 at Wageningen University (Holland). From 2008 she has been full professor. She was visiting professor at Universities in Spain, Greece, France, Germany. Research Interests:physicochemical, functional, technological and structural properties of proteins, modifications combined with structure and function relationships; effect of technology on the molecular and functional properties; identification of proteins and peptides by use of HPLC, MS, and UV spectroscopy; in silico, ex vivo and in vitro study of proteins and peptides in aspect of diet-related diseases.
Dubai Pharmacy College, UAE
Professions exist to serve society. Hence the mission of the pharmacy profession must address the needs of society and individual patients. To address the lack of highly skilled human resources, and existing skills should be upgraded to cope with the demands of delivering pharmaceutical care services. Personalized medicine is a high priority for the future of health care. Despite the use of most effective therapy, there are unfortunately several issues that accompany the use of the medications. Arguably the most significant issue among these is the prevalence of adverse drug reactions (ADR) and the failure of the drug to suppress the disease symptoms.
Pharmacists are among the most accessible and trusted health care professionals. Clinical pharmacists provide patient-oriented rather than product-oriented services. The accomplishments of a pharmacist will be achieved through gradual expansion of traditional roles. Personalized medicine (PM) is a high priority for the future of health care. PM may be considered an extension of traditional approaches to understanding and treating disease but with greater precision. A profile of a patientʼs gene variations can guide the selection of drugs or treatment protocols that minimize harmful side effects or ensure more successful outcomes. PM can also indicate an individualʼs susceptibility to certain diseases before they become manifest, allowing physicians and patients to design a plan for monitoring and prevention. Physicians can now go beyond the one-size-fits-all model of prescribing to make more effective clinical decisions for each patient.
Continuous, focused and concerted efforts of Physicians, Pharmacists & Nurses employing multidisciplinary approaches to treat disease, might enable achieving a health care professionalʼs mission of “zero new infections, zero discrimination and zero disease-related deaths.
Biography:
Dr. Mirza R. Baig is currently working as a Head of Clinical Pharmacy department in Dubai Pharmacy College. He did his PhD in Clinical Pharmacy from University Science Malaysia (USM), Malaysia. He worked in Malaysia, India and have international teaching and research experience of about 16 years. He published 4 books related to Clinical Pharmacy and Pharmaceutical Care. He published more than 40 Research papers and articles in International Journals. He is in the editorial board in various international journals, including reviewer for couple of Elsevier journals. He supervised numerous master and PhD students for their research projects. He also reviewed several Master and PhD thesis for Indian and foreign universities as an external examiner. He received many awards in his career, one of it as an outstanding scientist by a research foundation in India 2016.
1Saurashtra University, India
2S. J. Thakkar Pharmacy College, India
Cardimap tablet was standardize by modern scientific Quality control Procedures. Marketed formulation standardized according WHO guideline for herbal drug standardization using Lab prepared formulation. According to recent approach of standardization validated HPTLC methods using multiple markers such as Reserpine, Scopoletine, Piperine, Bacoside A and Lupeol were developed, both the formulation viz. marketed and lab formulation of Cardimap tablet was complies all the quality control parameters according to WHO guideline. High Performance Thin Layer Chromatography method for each marker compound showed a linear relationship with minimum r2 = 0.998 in the concentration range studied. The present methods were found to be precise of 0.03 to 0.7865 %RSD, specific, and accurate with a recovery of 99–101%, and hence can be used for routine analysis of this formulation, Standardization of marketed formulations using lab preparation according to WHO guideline highlights that marketed formulation is of comparable quality with lab preparation, further developed single HPTLC method could be used for standardization of marketed formulation using each marker for each plant of the formulation. This method could be used as routine quality control tool for standardization of this polyherbal formulation.
Biography:
Ms. Monika Balubhai Sangani has completed her M. Pharm at the age of 23 years from Gujarat Technological University and she receive grant from Government of India by Passing Graduate Pharmacy Aptitude Test (GPAT) and she is pursuing Ph. D studies from Saurashtra University, Department of Pharmaceutical Sciences, Gujarat, India.
Department of Pharmaceutical Chemistry, School of Pharmaceutical Education & Research, India
Statement of Research: Tyrosine kinase inhibitors and their potential in clinical application are well documented by dramatic examples like, Gleevec, Iressa and Nexavar etc. Several tyrosine kinase inhibitors are undergoing human trials and several are in the pipeline of drug discovery. Quick selection of epidemiologically relevant, drugable tyrosine kinase targets coupled to efficient lead finding and optimization needs more intervention in the area of high throughput cancer genome based molecular therapeutics. All these concerted effort may pave the silver lining to tailor made personalized cancer therapeutics.
Experimental & Theoretical Orientation: Keeping in view their importance, twenty new substituted indolin-2-one containing imine derivatives (2a-2t) were synthesized and docked with eight different tyrosine kinase enzymes (Aurora A Kinase PDB: 3FDN, Aurora B Kinase PDB: 2VRX, human Abl kinase PDB: 3CS9, human CDK6-VCYCLIN PDB: 2EUF, C-MET PDB: 4XMO, EGFR PDB: 1M17, Focal Adhesion Kinase PDB: 2JKK, human VEGFR-2 PDB: 3VHE). On the basis of docking results, VEGFR-2 target was selected out of all kinase targets for the in-vitro enzyme assay. Enzymatic inhibition assay was performed for all twenty compounds using VEGFR-2 enzyme inhibition assay kit and IC50 was obtained for all compounds. Simultaneously, all compounds were sent to NCI, USA for sixty-cell line based anticancer screening, out of which fifteen compounds were selected for one dose anticancer assay.
Findings: Compounds 2a (NSC: D-795068/1) and 2g (NSC: D-795071/1) were found potent during one dose anticancer screening and fulfilled the specified threshold for growth inhibition criteria of NCI and further selected for full panel five dose assay at 10-fold dilutions of five different concentrations. Both compounds 2a and 2g displayed Mid GI50 values of 1.69 µM & 1.54 µM respectively against the cell lines of Leukemia, Non-Small Cell Lung Cancer, Colon Cancer, CNS Cancer, Melanoma, Ovarian Cancer, Renal Cancer, Prostate Cancer and Breast Cancer.
Conclusion: The results were found even better than the standard used (Fluorouracil) by NCI. In silico studies and ADME prediction also supported the potential of these compounds as tyrosine kinase inhibitors. It is expected that Tyrosine Kinase inhibition by the said compounds may deliberate a substantial therapeutic benefit over existing treatments for cancer.
Biography:
Nishtha Shalmali is presently working on development of new tyrosine kinase inhibitor compounds as a PhD Scholar in the Department of Pharmaceutical Chemistry, School of Pharmaceutical Education & Research, Jamia Hamdard. She has recently qualified CSIR-SRF and secured 2nd Best Poster Award for her groupʼs research work on thiazole-5-carboxylate derivatives as selective MAGL inhibitors at ITS, Ghaziabad (India). She has emerged as an effective presenter during various conferences. Nishtha has attained hands on specific skills in the field of Green Chemistry, Scale up techniques and Bulk drugs during her Post Graduation & has achieved impressive hold on medicinal, pharmaceutical & analytical laboratory techniques during her doctoral research.
1Department of Drug Delivery, Disposition and Dynamics, Monash University Australia
2Department of Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Australia
3Priority Research Centre in Reproductive Science, University of Newcastle, Australia
This in vitro study aimed to investigate the synergistic antibacterial activity of polymyxin B in combination with 2 nm silver nanoparticles (NPs) against Gram-negative pathogens commonly isolated from the cystic fibrosis (CF) lung.
The in vitro synergistic activity of polymyxin B with silver NPs was assessed using the checkerboard assay against polymyxin-susceptible and polymyxin-resistant Pseudomonas aeruginosa isolates from the lungs of CF patients. The combination was also examined against the Gram-negative species Haemophilus influenzae, Burkholderia cepacia, Burkholderia pseudomallei, Stenotrophomonas maltophilia, Klebsiella pneumoniae and Acinetobacter baumannii that are less common in the CF lung. The killing kinetics of the polymyxin B-silver NPs combinations was assessed against P. aeruginosa by static time-kill assays over 24 h. Polymyxin B and silver NPs alone were not active against polymyxin-resistant (MIC ≥ 4 mg/L) P. aeruginosa. Whereas, the combination of a clinically-relevant concentration of polymyxin B (2 mg/L) with silver NPs (4 mg/L) successfully inhibited the growth of polymyxin-resistant P. aeruginosa isolates from CF patients as demonstrated by ≥2 log10 decrease in bacterial count (CFU/mL) after 24 h. Treatment of P. aeruginosa cells with the combination induced cytosolic GFP release and an increase of cellular reactive oxygen species. In the nitrocefin assay, the combination displayed a membrane permeabilizing activity superior to each of the drugs alone.
The combination of polymyxin B and silver NPs displays excellent synergistic activity against highly polymyxin-resistant P. aeruginosa and is potentially of considerable clinical utility for the treatment of problematic CF lung infections.
Biography:
Raad Jasim was born in Babylon, Iraq, in 1977. He received the bachelor degree in pharmaceutical sciences from Baghdad University, Iraq, in 2002. He worked as a pharmacist in the City of Medicine / Hospital of Special Surgeries, in Baghdad/ Iraq from December 2002 to October 2004. In November 2004 he joined the department of pharmacology and Therapeutics, Almustansria University/ College of Pharmacy as a demonstrator. In 2008 he received the Master degree in Pharmacology & Therapeutics from Kufa University/College of Medicine/Department of Pharmacology & Therapeutics, Iraq. In 2014 he has started his PhD in the department of Drug Delivery, Disposition and Dynamics (D4), Monash Institute of Pharmaceutical Sciences, Monash University, Australia.
Annamalai University, India
The two elements of key importance in the treatment of cancer includes early correct diagnosis and effective interventional therapy. Predicting the response to pharmacological intervention is an optimal goal for healthcare professionals especially in cancer prognosis. Metastasis of cancer indicates a morbid state resistant to standard pharmacotherapeutic interventions. A terminology ‘Companion Diagnostics ʼimproves predictability of outcomes and holds the promise as a strategic tool for the oncologist to decide which drug would be best suited to treat a particular cancer.
Immunohistochemistry (IHC) has emerged as a reliable and sensitive investigative tool that provides supplemental information to the routine morphological assessment of tissues. The use of IHC to study cellular markers that define specific phenotypes has provided important diagnostic, prognostic and predictive information relative to the disease status and normal cellular biology. Application of antibodies to the molecular study of tissue pathology has been refined and improvised, particularly for use in fixed tissues. In contrast to solution based immunoassays that detect relatively abundant native proteins, the preservation of antigen in fixed tissues is variable and unpredictable. Evolution of newer techniques has resolved these issues and has helped detect proteins in tissues with great sensitivity. It also provides a semi-quantitative assessment, with the ultimate goal of integrating tissue based analysis with proteomic information. Targeted therapies have created a need for a more profound quantitative biomarker information. These newly launched IHC tests are termed as ‘prognostic markers’, ‘predictive markers’ and “advanced personalized diagnostics”.
Biography:
Dr. Vanitha Samuel is a Medical graduate from Stanley Medical College, (1986-1991) Chennai, Tamil Nadu, India. She has completed her Master degree in Pharmacology (1999) at Madras Medical College, Chennai and her PhD in Pharmacology at Rajah Muthaiah Medical College, Annamalai University, Chidambaram, where she is currently working as Professor in the Department of Pharmacology. She is a member of the Pharmacovigilance Committee in RMMC and her speciality and field of research includes Toxicology related drug effects and study of drugs that ameliorate them. Her professional interests involves the pre-clinical evaluation of various flavonoid compounds in some selective cancers.
Queenʼs University Belfast, UK
Most cancer chemotherapeutics lack tissue specificity, resulting in many undesirable side effects. Selective drug delivery to the tumour tissues could ultimately increase local drug concentrations at the tumor without the need to escalate the administrated doses in patients. A wide range of drug delivery systems has been developed to alter the pharmacokinetics of drug molecules, and enhance their tumour targeting. Furthermore, several approaches have been explored to increase the bioavailability of drugs at the site of action, utilising the unique characteristics of the tumour microenvironment, such as overexpressed enzymes, acidic pH, and hypoxia, or using external triggers, such as heat, ultrasound, and light. In this talk will describe the latest delivery systems that we have developed in our laboratory to enhance the tumour accumulation of anticancer drugs, utilising internal and external triggers.
Biography:
Dr Al-Jamal is an overseas and a UK-registered pharmacist. She completed her PhD in Drug Delivery and Nanomedicine in 2008 at UCL School of Pharmacy, London. She is currently a Reader in Drug Delivery and Nanomedicine at The School of Pharmacy, Queenʼs University Belfast, UK. She is also a Prostate Cancer Research Fellow working on developing novel nanomedicine to treat advanced prostate cancer in men. She worked at the University of Ease Anglia, Norwich, as a Lecturer in Drug Delivery and Nanomedicine (2013-2017), after working as a Senior Research Fellow at University College London and Kingʼs College London (2009-2013).
Dr Al-Jamalʼs main research interests focus on engineering novel nanomaterials for biomedical applications. Her current research, in Cancer Nanomedicine, aims to design smart vectors to deliver a wide range of therapeutic agents and targeting moieties, and to fabricate multifunctional nanoparticles for combinatory therapy and theranostic applications. Her long-term research career is to facilitate the translation of nanoparticle-based therapeutics from the lab to the clinic. Wafa is the GSK Emerging Scientist Award winner for 2015, and Gro Brundtland Award winner for 2017. She has published over 40 papers in high impact journals. Currently, she is a Visiting Professor at Guizhou Medical School, China.
Contact us for any additional information - contact@madridge.org
Madridge Publishers is licensed under a Creative Commons Attribution 4.0 International License.